drugset / Trial / NCT00332657
Anecortave Acetate Risk Reduction Trial (AART)
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of dry age-related macular degeneration (AMD) in patients who are at-risk for progressing to wet AMD.
Timeline
- Start
- 2006-09
- Primary completion
- 2008-12
- Completion
- 2008-12
Outcome
Outcome not reported
Stopped: “Management Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anecortave Acetate | Unknown | 15 mg | Other |
| Subject | Anecortave Acetate | Unknown | 30 mg | Other |
Indications
No indication recorded.